<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65567">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02064738</url>
  </required_header>
  <id_info>
    <org_study_id>2013-P002683</org_study_id>
    <nct_id>NCT02064738</nct_id>
  </id_info>
  <brief_title>High Omega-3/Low Omega-6 Treatment Diet for Aspirin-exacerbated Respiratory Disease (AERD)</brief_title>
  <official_title>A Pilot Study of the Effectiveness of a High Omega-3/Low Omega-6 Treatment Diet for Treating Aspirin-exacerbated Respiratory Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to test the hypothesis that a treatment diet low in omega-6
      fatty acids and high in omega-3 fatty acids can cause improvement in asthma symptoms, nasal
      symptoms, and pulmonary function in patients with aspirin-exacerbated respiratory disease
      (AERD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in urinary leukotriene E4 levels</measure>
    <time_frame>2 weeks and 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum leukotriene B4 levels</measure>
    <time_frame>2 weeks and 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in asthma control questionnaire score</measure>
    <time_frame>Baseline, 2 weeks, and 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sino-Nasal Outcome Test-22 (SNOT-22) score</measure>
    <time_frame>Baseline, 2 weeks, and 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in forced expiratory volume in one second  (FEV1), forced vital capacity   (FVC), and FEV1/FVC</measure>
    <time_frame>Baseline, two weeks, and four weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in urinary prostaglandin D2 level</measure>
    <time_frame>2 weeks and 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in blood eosinophil count</measure>
    <time_frame>2 weeks and 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in platelet-leukocyte aggregates</measure>
    <time_frame>2 weeks and 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>ASA Triad</condition>
  <condition>Asthma, Nasal Polyps, And Aspirin Intolerance</condition>
  <arm_group>
    <arm_group_label>Normal diet</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Two weeks of unaltered diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low omega-6/high omega-3 diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams</intervention_name>
    <arm_group_label>Low omega-6/high omega-3 diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of physician-diagnosed asthma

          -  History of nasal polyposis

          -  History of at least two reactions to oral aspirin or other nonselective
             cyclooxygenase inhibitor with features of lower airway involvement (cough, chest
             tightness, wheezing, dyspnea), or diagnosis of AERD via a physician-conducted
             challenge to aspirin

          -  Age between 18 and 70 years

        Exclusion Criteria:

          -  Current smoking, defined as daily tobacco smoking in the last 6 months and at least
             one instance of tobacco smoking in the last 3 months.

          -  Current pregnancy or breastfeeding

          -  BMI &lt;20

          -  History of allergy to fish or any unwillingness to eat fish as a regular part of the
             diet

          -  Use of Zyflo (zileuton) in the last two weeks

          -  Presence of an implantable cardioverter-defibrillator

          -  Use of oral steroids in the last two weeks

          -  Participation in any other clinical trial in the last month

          -  Any use of nonsteroidal antiinflammatory drugs (NSAIDs) or any drug that inhibits the
             cyclooxygenase enzyme during the course of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanya M Laidlaw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tanya M Laidlaw, MD</last_name>
    <phone>6175251034</phone>
    <email>tlaidlaw@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christina Johns</last_name>
    <phone>6175251267</phone>
    <email>cjohns1@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya M Laidlaw, MD</last_name>
      <phone>617-525-1034</phone>
      <email>tlaidlaw@partners.org</email>
    </contact>
    <investigator>
      <last_name>Tanya M Laidlaw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine N Cahill, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paige Wickner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Carlos Cardet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aerd.partners.org</url>
    <description>Brigham and Women's Hospital AERD website</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>February 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Tanya Laidlaw, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>Omega-3 fatty acids</keyword>
  <keyword>Omega-6 fatty acids</keyword>
  <keyword>aspirin exacerbated respiratory disease</keyword>
  <keyword>AERD</keyword>
  <keyword>Samter's Triad</keyword>
  <keyword>nasal polyp</keyword>
  <keyword>aspirin</keyword>
  <keyword>diet</keyword>
  <keyword>leukotriene</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nasal Polyps</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
